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Available online 14 April 2016Objective: To report our experience using ipilimumab, a monoclonal antibody targeting CTLA-4, combined with
radiation therapy in women diagnosed with mucosal melanoma of the lower genital tract.
Methods:We retrospectively identiﬁed all patients who received ipilimumab with concurrent radiation treat-
ment of mucosal melanoma of the lower genital tract at Memorial Sloan Kettering Cancer Center from 2012 to
2015. Various clinicopathologic data and treatment response were abstracted and analyzed.
Results: Four patients were identiﬁed. Median age was 61.5 years (range 44–68); 3 were diagnosed with vaginal
melanoma, 1 with cervical melanoma. All would have required extensive surgical procedures to remove entirety
of disease. Median size of lesions was 4.7 cm (range, 3.3–5.3); all were Ballantyne stage I. Median number of
doses of upfront ipilimumab was 4 (range, 3–4). Two patients suffered CTCAE grade 3 adverse events (colitis,
rash). All received external beam radiation: 3 to 3000 cGy, 1 to 6020 cGy. Post-radiation surgical resection was
performed in 3 patients (75%); 1 (33%) of 3 patients achieved complete pathologic response. Complete local ra-
diographic response was observed in all patients after completion of initial therapy and surgery. Two developed
recurrence at 9 and 10 months post-diagnosis (mediastinum, lung); 2 remain disease-free at 20 and 38 months.
Conclusions:Mucosal melanoma of the lower genital tract is rare, and data-driven treatment strategies limited.
Immunotherapy has demonstrated durable efﬁcacy in the treatment of cutaneousmelanomas. Our small case se-
ries shows a favorable response to combined ipilimumab and radiation therapy. Larger studies are needed to val-
idate these promising results.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Mucosal melanoma accounts for approximately 1.4% of all melano-
mas diagnosed in the United States (Mihajlovic et al., 2012). The subset
of mucosal melanoma localized to the lower genital tract (LGT) consti-
tutes a small percentage of these rare tumors. The Surveillance Epidemi-
ology and End Results database noted only 644 cases of vulvar
melanoma from 1973 to 2003 (Sugiyama et al., 2007). Thirty-seven
cases of newly diagnosed vaginal melanoma were reported at MD An-
derson Cancer Center over a similar time frame (1980–2009)upport Grant P30 CA008748.
partment of Surgery, Memorial
llege, 1275 York Avenue, New
. This is an open access article under(Frumovitz et al., 2010). Cervical melanoma is the rarest of these tu-
mors, comprising 3–9% of all diagnosed mucosal melanomas of the
LGT (Pusceddu et al., 2012; Myriokefalitaki et al., 2013). Survival for pa-
tients with this rare malignancy remains poor. A recent study from our
institution reported 5-year overall survival (OS) rates of 60% for patients
with vulvar melanoma and 20% for those with vaginal melanoma, in a
cohort of 118 patients (Leitao, 2014).
Given the rarity of mucosal melanoma of the LGT, much of the data
regarding treatment and care has been extrapolated from larger studies
that include cutaneous and mucosal melanomas of varied origin. The
mainstay of treatment for these tumors is primary surgical resection,
with the goal of achieving negative margins (Garbe et al., 2010). How-
ever, this goal is often difﬁcult to achieve in melanomas of the LGT
due to close approximation of tumor to vital anatomic structures such
as the bladder and rectum. Attempting to obtain negative margins
through an exenterative type of procedure is not recommended in thisthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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no survival beneﬁt (Leitao, 2014; DeMatos et al., 1998a; Brand et al.,
1989). Exploration of preoperative treatment with chemotherapy and/
or radiation to circumvent the need for extensive surgical resection
has been limited (Leitao et al., 2014). Standard chemotherapeutics
such as dacarbazine, which are FDA-approved for use in advanced cuta-
neous melanoma, show limited activity in the metastatic setting, and
trials of neoadjuvant chemotherapy for patients with resectable mela-
noma indicate that they are no more likely to respond than those with
stage IV disease (Shah et al., 2010). Radiation treatment has customarily
been used in the palliative setting forwomenwith advanced, symptom-
atic disease (Huguenin et al., 1998).
More recently, the role of immunotherapy in cutaneous melanoma
has been explored, with favorable results (Larkin et al., 2015; Robert
et al., 2011; Hodi et al., 2010). A 2010 phase 3 study investigating the
use of ipilimumab–a monoclonal antibody that blocks cytotoxic T-
lymphocyte-associated antigen 4 (CTLA-4)–in patients with previously
treated metastatic melanoma demonstrated a nearly 4-month OS ad-
vantage as compared to a peptide vaccine alone (Hodi et al., 2010). Re-
cent literature has also pointed to a potential modulation of the
immunotherapeutic effect of CTLA-4 blockade with concomitant radia-
tion (Postow et al., 2012; Twyman-Saint Victor et al., 2015). In this
case series, we report on our experience using combined ipilimumab
and radiation in the treatment of women diagnosed with mucosal mel-
anoma of the LGT.
2. Methods
After Institutional Review Board approval, we retrospectively identi-
ﬁed all patients at Memorial Sloan Kettering Cancer Center who re-
ceived ipilimumab with concurrent radiation for treatment of mucosal
melanoma of the LGT between 2012 and 2015. Review was based on
data collected from outpatient, operative, and radiation oncology
notes. Demographic data collected included age, race, body mass
index (BMI), documented comorbidity, and genetic mutational status.
Initial date of diagnosis and pathologic tumor features were noted.
Use of ipilimumab and number of doses received, as well as radiation
treatment and dosage, were captured. Retrospective toxicity grading
was as per the Common Terminology Criteria for Adverse Events
(CTCAE) version 4.0 (NCI 2009).
Treatment responsewas graded as per RECIST guidelines version 1.1,
and retrospectively reviewed (Eisenhauer et al., 2009). A complete re-
sponse (CR) was deﬁned as disappearance of all target lesions, with
any pathological lymph nodes demonstrating a reduction in short axis
to b10 mm. Partial response (PR) was characterized by a minimum
30% decrease in the sum of diameters of target lesions, taking as refer-
ence the baseline sum diameters. Stable disease (SD) was deﬁned as
neither sufﬁcient shrinkage to qualify for PR nor sufﬁcient increase toTable 1
Clinicodemographic summary of patients with melanoma of the lower genital tract.
Patient A Patient B
Primary site Vagina Vagina
Age 44 68
BMI 20.4 23.7
Pathology IHC staining Melan-A, MITF, HMB-45 MITF, HMB-45
Ipilimumab doses 4 4
Radiation therapy EBRT 3000 cGy EBRT 6020 cGy
Post-Ipi/RT imaging SD PR
Surgical resection Vaginectomy WLE
Post-op imaging CR CR
Recurrence No Yes
Vital status NED DOD
BMI= bodymass index, IHC= immunohistochemistry, Melan-A=melanoma antigen, MITF=
EBRT = external beam radiation therapy, Ipi = ipilimumab, SD= stable disease, PR= partial
oophorectomy, NED = no evidence of disease, DOD = dead of disease, AWD= alive with dise
All patients had a documented local CR postoperatively.qualify for disease progression. Deﬁnition of response as CR, PR, or SD
was establishable only if no new lesions arose during treatment. Recur-
rence of disease was based on pathologic or radiographic evidence. OS
was measured from date of initial diagnosis until date of death or until
most recent known status in patients who were still alive at the time
of data collection.
3. Results
Four patients with mucosal melanoma of the LGT treated with con-
current ipilimumab and radiation were identiﬁed (Table 1). Three pa-
tients were diagnosed with vaginal melanomas, and 1 patient was
diagnosed with a cervical melanoma (Fig. 1).
3.1. Patient A
Patient A is a 44-year-old Caucasian female who initially presented
with vaginal discharge. She was found to have a 4.7 cm, nearly
completely circumferential vaginal tumor encompassing the right-
upper andmid vagina, precluding primary surgical resection. No distant
disease was noted on imaging at time of initial diagnosis. Biopsy con-
ﬁrmed a Ballantyne stage I vaginal melanoma. Genetic testing was neg-
ative for mutations in BRAF, NRAS, or c-KIT. Patient A received
treatment with 4 doses of ipilimumab at 3 mg/kg, delivered intrave-
nously every 3 weeks. The treatment course was complicated by a
CTCAE grade 3 generalized maculo-papular rash, which responded to
outpatient therapy with topical and oral steroids; and a CTACE grade 1
diarrhea. Concurrent treatment with external beam radiation (EBRT)
was given to a dose of 3000 cGy in 5 fractions. Post-treatment imaging
after completion of EBRT demonstrated SD. The patient underwent sur-
gical resection with a partial vaginectomy 33 days after completion of
EBRT. Final pathology revealed no evidence of disease in the surgical
specimen, and postoperative imaging showed no evidence of residual
disease. Patient A subsequently received maintenance ipilimumab
every 12weeks for 1 year at an outside institution. No recurrence of dis-
ease was noted at 38 months of follow-up.
3.2. Patient B
Patient B is a 68-year-old Asian female who initially presented with
vaginal bleeding. She was found to have a 3.3 cm multifocal vaginal le-
sion. Pathologywas consistentwith a Ballantyne stage I vaginalmelano-
ma. No distant diseasewas noted on imaging at time of initial diagnosis.
Genetic testing revealed nomutations in BRAF, NRAS, or c-KIT. Patient B
received 4 doses of ipilimumab with no complications, followed by
EBRT to 6020 cGy in 28 fractions. Imaging after completion of initial
treatment demonstrated a partial radiographic response. Fifty-seven
days post-radiation, surgical resection with wide local excision wasPatient C Patient D
Vagina Cervix
61 62
24.4 26
Melan-A, MITF, HMB-45, tyrosinase Melan-A, HMB-45, S100
4 3
EBRT 3000 cGy EBRT 3000 cGy
CR SD
n/a Hysterectomy, BSO, vaginectomy
CR CR
No Yes
NED AWD
microphthalmia-associated transcription factor, HMB-45= humanmelanoma black 45,
response, CR= complete response, WLE=wide local excision, BSO = bilateral salpingo-
ase.
Fig. 1. Survival outcomes in patients with melanoma of the LGT treated with ipilimumab and radiation.
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surgical margins. The patient received adjuvant therapy with combina-
tion cisplatin and dacarbazine for 5 cycles. Follow-up imaging at
3 months post-surgery demonstrated a complete local radiographic re-
sponse. Recurrence of disease with lung metastases was noted at
10 months following initial diagnosis, and 6 months following comple-
tion of treatment with ipilimumab and radiation. Patient B died of dis-
ease 16 months after initial diagnosis.
3.3. Patient C
Patient C is a 61-year-old Black female who initially presented with
vaginal bleeding. She was found to have an unresectable stage I vaginal
melanoma encompassing the entire vaginal canal. No evidence of dis-
tant disease was identiﬁed at that time. No genetic testing was per-
formed. Four doses of ipilimumab at 3 mg/kg were given, without
complication. The patient subsequently received EBRT to 3000 cGy in
5 fractions. Post-treatment imaging demonstrated a complete radio-
graphic response to initial therapy. No surgical intervention was per-
formed and no additional treatment given. Patient C showed no
evidence of disease recurrence at 20months following initial diagnosis.
3.4. Patient D
Patient D is a 62-year-old Asian female who initially presented with
vaginal bleeding. Shewas found to have a 5.3 cmcervicalmass adherent
to the rectum, involving the vagina and anus. The lesion was consistent
with a Ballantyne stage I primary cervical melanoma. No distant disease
was identiﬁed on imaging at time of initial diagnosis. Genetic testing re-
vealed no evidence of BRAF, NRAS, or c-KIT mutations. Patient D re-
ceived only 3 doses of ipilimumab, due to dose-limiting CTCAE grade 3diarrhea. She initially required treatment with oral steroids, and was
subsequently hospitalized and treated with inﬂiximab for severe
steroid-refractory colitis. The patient was also noted to have an infusion
reaction during treatment, characterized by chest and back pain and
shortness of breath, with a negative cardiac work-up. She received
post-ipilimumab EBRT to 3000 cGy in 5 fractions. Imaging after comple-
tion of EBRT demonstrated SD. The patient underwent hysterectomy
with bilateral salpingo-oophorectomy and upper vaginectomy 97 days
after completing treatment. Final pathology revealed presence of dis-
ease, with negative surgical margins. A complete radiographic response
was noted on post-operative imaging 3 weeks after surgery. On surveil-
lance imaging 6 months after completing initial treatment with
ipilimumab/radiation and 9 months following initial diagnosis, the pa-
tient was found to have a metastatic mediastinal lymph node. Patient
D remains alive with disease 19 months after initial diagnosis and has
been treated with pembrolizumab for recurrent disease, with SD noted.
4. Discussion
Mucosal melanoma of the LGT is rare, and data-driven treatment
strategies remain limited. In this study, we present 4 cases of mucosal
melanoma of the vagina and cervix that, at time of diagnosis, would
have required an extensive surgical procedure to remove the entirety
of disease; however, all 4 patients received initial treatmentwith a com-
bination of concurrent ipilimumab and radiation. Ipilimumab was
dosed at 3mg/kg IV every 3weeks as per the FDA approval for advanced
melanoma. The clinicodemographic features of the patients in our study
are in keepingwith known characteristics of patients withmelanoma of
the LGT, including common presentation and age at initial diagnosis. All
4 patients received a minimum of 3 doses of ipilimumab with concur-
rent EBRT. CTCAE grade 3 adverse effects of colitis and rash were
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severity of symptoms. Three patients with persistent disease after
ipilimumab/radiation underwent less extensive surgical resection. All
patients demonstrated local CR after completing initial treatment. Two
patients have remained without disease recurrence since that time.
Immunotherapy has demonstrated efﬁcacy in the treatment of cuta-
neous melanomas, with durable effects. The initial results of a phase 3
study of metastatic melanoma, comparing the addition of ipilimumab
to a glycoprotein peptide vaccine (gp100), showed an improvement in
median OS of 10 months, as compared to 6.4 months in patients receiv-
ing gp100 alone (Hodi et al., 2010). A 2011 study of previously untreat-
ed patients with metastatic disease also demonstrated a signiﬁcantly
prolonged OS in patients receiving ipilimumab with dacarbazine
(DTIC), a standard alkylating chemotherapeutic drug, in contrast to
those receiving dacarbazine alone (Robert et al., 2011). Notably,
patients in this study undergoing combination therapy also achieved
durable results, with survival rates at 3 years of 20.8% for the
ipilimumab-containing regimen and 12.2% for the DTIC-alone regimen.
In a more recent analysis of OS in ipilimumab-treated patients with ad-
vancedmelanoma, pooled data from10prospective trials demonstrated
amedian OS of 11.4months, with a plateau in the survival curve around
year 3, and survival rates ranging from 20 to 26% (Schadendorf et al.,
2015). Additional immunotherapeutic regimens have shown further
promise, including the addition of PD-1 checkpoint inhibitors
nivolumab to an ipilimumab-containing regimen and pembrolizumab
for patients with ipilimumab-refractory melanoma (Larkin et al.,
2015; Ribas et al., 2015).
Although typically conﬁned to case series and single-institution
studies, data regarding the treatment and survival outcomes of patients
with mucosal melanoma of the LGT illustrate a difﬁcult-to-control dis-
ease with poor outcomes in all stages (Brand et al., 1989; Leitao et al.,
2014; DeMatos et al., 1998b; Harting and Kim, 2004; Kingston et al.,
2004; Bennani et al., 2013). Historically, 5-year survival rates for pa-
tients with vaginal melanoma have been calculated to be as low as 5–
10% (Harting and Kim, 2004). In a 1989 case series from UCLA, the OS
for 7 cases of primary vaginal melanoma was 13% (Brand et al., 1989).
More recent data demonstrate 5-year survival rates of 20% for patients
with vaginal melanoma (Frumovitz et al., 2010; Leitao, 2014). In a liter-
ature review of 78 cases of cervical melanoma, 5-year survival rates in
patients with stage I and stage II disease were 18.8% and 11.1%, respec-
tively (Pusceddu et al., 2012). Over a period of 25 years at Duke Univer-
sity Medical Center, a total of 30 patients with vulvar mucosal
melanoma, 9 patients with vaginal mucosal melanoma, and 4 patients
with cervical mucosal melanoma were diagnosed (DeMatos et al.,
1998a). Although two-thirds of these patients were found to have local-
ized disease at time of initial diagnosis, and all but 1 patient underwent
resection with curative intent, the majority of treatment failures were
local. Outcomes for patients with advanced disease are even more dis-
mal; in a 2004 study fromUTHouston andMDAnderson Cancer Center,
only 4 of 11 patients with advanced vulvovaginal melanoma demon-
strated a PR to biochemotherapy, and none showed a CR (Harting and
Kim, 2004). Clearly, novel therapeutics and treatment strategies for
this rare malignancy are needed.
Although limited by small numbers, our case series shows that
select patients can receive concurrent neoadjuvant radiation and check-
point inhibition to reduce the morbidity of a planned surgical
resection—which, historically, has a low chance of systemic cure. Our
ﬁndings are particularly interesting in light of the known relatively
radio-resistant nature of melanoma, as well as previous studies
reporting high rates of adverse events in patients undergoing radiation
treatment combined with other immunotherapies (Barker et al., 2013).
However, recent studies showing the efﬁcacy of ipilimumab used con-
currently with radiation in patients with metastatic melanoma high-
light the potential synergy of this combination (Postow et al., 2012;
Bot et al., 2012; Patel et al., 2015; Kiess et al., 2015; Silk et al., 2013).
In a 2013 retrospective review of 29 patients at Memorial SloanKettering Cancer Center with unresectable, advanced melanoma, who
underwent non-brain radiation with induction or maintenance
ipilimumab, the combination of these two therapies did not appear to
compromise local effect or survival beneﬁts (Barker et al., 2013). A re-
cently published phase 1 study from the University of Pennsylvania of
22 patients with metastatic melanoma also demonstrated promising
results, with an overall response rate of 36% in patients receiving com-
bined therapy (Twyman-Saint Victor et al., 2015).
Participation in clinical trials, when available, should be strongly en-
couraged for patients with gynecologic mucosal melanoma of the LGT.
Providers should advocate for inclusion of gynecologic patients in
large prospective trials of melanoma patients, given the overall rarity
of this tumor type and the potential utility of immunotherapy and
novel treatments in this patient population. The importance of a multi-
disciplinary approachwith involvement of amelanoma specialist is par-
amount, and provides the best opportunity for disease control and cure.Conﬂict of interest statement
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